{"transactions":[{"id":904913,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-13T21:05:22.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":93037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."}],"balance_after":93037,"derivative":{"exercise_price":3.24,"expiration_date":"2036-02-11","underlying":"Common Stock","underlying_shares":93037},"source":{"system":"sec-edgar","filing":"0001140361-26-005409","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126005409/form4.xml","form_type":"4"}},{"id":904912,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:05:22.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":61963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Holdings include Restricted Stock Units (\"RSUs\") that convert to common stock on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Holdings include Restricted Stock Units (\"RSUs\") that convert to common stock on a one-for-one basis."}],"balance_after":407874,"source":{"system":"sec-edgar","filing":"0001140361-26-005409","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126005409/form4.xml","form_type":"4"}},{"id":1021374,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-08T19:39:39.000Z","date":"2025-10-06","kind":"grant","planned":false,"acquired":true,"shares":383854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents non-qualified stock options (\"NQSOs\") that convert to common stock on a one-for-one basis.  One-third (1/3) of such NQSOs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents non-qualified stock options (\"NQSOs\") that convert to common stock on a one-for-one basis.  One-third (1/3) of such NQSOs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."}],"balance_after":383854,"derivative":{"exercise_price":3.18,"exercise_date":"2028-10-06","expiration_date":"2035-10-06","underlying":"Common Stock","underlying_shares":383854},"source":{"system":"sec-edgar","filing":"0001140361-25-037683","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125037683/form4.xml","form_type":"4"}},{"id":1021373,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-08T19:39:39.000Z","date":"2025-10-06","kind":"grant","planned":false,"acquired":true,"shares":62893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries."}],"balance_after":345911,"source":{"system":"sec-edgar","filing":"0001140361-25-037683","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125037683/form4.xml","form_type":"4"}},{"id":1021372,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-08T19:39:39.000Z","date":"2025-10-06","kind":"grant","planned":false,"acquired":true,"shares":283018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis.  One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis.  One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis.  One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."}],"balance_after":283018,"source":{"system":"sec-edgar","filing":"0001140361-25-037683","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125037683/form4.xml","form_type":"4"}},{"id":1306632,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:10:39.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":3.1,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001415889-25-001083","document":"form4-01082025_070134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001083/form4-01082025_070134.xml","form_type":"4"}},{"id":1306631,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-08T14:10:39.000Z","date":"2025-01-08","kind":"other","planned":false,"acquired":false,"shares":185000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent (\"Merger Sub\").  On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $9.00 per Share in cash (the \"Cash Amount\"), and (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").  Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent (\"Merger Sub\").  On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $9.00 per Share in cash (the \"Cash Amount\"), and (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").  Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-001083","document":"form4-01082025_070134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001083/form4-01082025_070134.xml","form_type":"4"}},{"id":1549606,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-04-03T16:03:59.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date, and the remaining shares will vest in 42 equal monthly installments thereafter."}],"balance_after":250000,"derivative":{"exercise_price":3.1,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-24-041039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024041039/ownership.xml","form_type":"4"}},{"id":1549605,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-03T16:03:59.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's 2022 Inducement Plan. The RSUs are scheduled to vest in four equal annual installments."}],"balance_after":185000,"source":{"system":"sec-edgar","filing":"0000950170-24-041039","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024041039/ownership.xml","form_type":"4"}},{"id":1995275,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option to purchase Common Stock","published_at":"2023-02-23T22:09:37.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":131000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":131000,"derivative":{"exercise_price":6.12,"expiration_date":"2033-02-20","underlying":"Common Stock","underlying_shares":131000},"source":{"system":"sec-edgar","filing":"0001619856-23-000020","document":"wf-form4_167719014984142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000020/wf-form4_167719014984142.xml","form_type":"4"}},{"id":2049386,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-20T21:13:22.000Z","date":"2023-01-19","kind":"sale","acquired":false,"shares":5627,"price":6.31,"value":35506.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units as provided in standing \"sell to cover\" instructions."}],"balance_after":59373,"source":{"system":"sec-edgar","filing":"0001619856-23-000002","document":"wf-form4_167424918505378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000002/wf-form4_167424918505378.xml","form_type":"4"}},{"id":2426357,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option to purchase common stock","published_at":"2022-01-26T00:56:14.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":161250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to this option will vest on January 18, 2023 and an additional 1/48th of the aggregate number of shares subject to the option will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates."}],"balance_after":161250,"derivative":{"exercise_price":10.64,"expiration_date":"2032-01-24","underlying":"Common stock","underlying_shares":161250},"source":{"system":"sec-edgar","filing":"0001209191-22-004860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000120919122004860/doc4.xml","form_type":"4"}},{"id":2426356,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":66474,"kind":"person","name":"Rizvi Syed Ali-aamir","position":1,"cik":"0001897621","reported_name":"Rizvi Syed Ali-aamir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2022-01-26T00:56:14.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects restricted stock units (\"RSUs\") that vest in four equal annual installments beginning on January 18, 2023, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001209191-22-004860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000120919122004860/doc4.xml","form_type":"4"}}]}